Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, are presented today by Dr. Erica Mayer of Dana-Farber Cancer Institute at the annual meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany.

Living near toxic sites is linked to aggressive breast cancer. Can AI improve mammography interpretation? Glioblastoma cells that “unstick” from neighboring cells become more deadly, and patients who receive remote monitoring after cancer surgery have better outcomes. All of these story ideas and more are in this month’s tip sheet from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Breast cancer is increasingly affecting younger women globally, often before the screening guidelines recommend testing age. Young patients with breast cancer have a worse prognosis than older women.

Early screening through AI-enhanced mammography and high-throughput sequencing-powered genetic tests can identify high-risk individuals, offering a critical time frame for prevention and intervention.

Breast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the main causes of cancer-related mortality. Precisely predicting whether this type of tumour will reappear remains one of the key challenges in oncology. To try and make progress in this field, an international team led by the Universitat Rovira i Virgili has developed an artificial intelligence model that brings together medical imaging data and clinical information to calculate the risk of tumour recurrence in a much more accurate and interpretative way.